Cargando…

Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers

OBJECTIVES: Two randomized, controlled studies comparing outcomes in patients treated with direct oral anticoagulants or low-molecular weight heparin for cancer-associated venous thromboembolism (VTE) have previously been performed. However, gynecologic cancers accounted for approximately 10% of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jang Ho, Lee, Joo Hee, Jo, Kyung-Wook, Huh, Jin-Won, Oh, Yeon-Mok, Lee, Jae Seung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918888/ https://www.ncbi.nlm.nih.gov/pubmed/31789000 http://dx.doi.org/10.3802/jgo.2020.31.e10

Ejemplares similares

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019)

Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism
por: de Jong, Lisa A, et al.
Publicado: (2020)

Management of venous thromboembolism in patients with cancer: role of dalteparin
por: Linkins, Lori-Ann
Publicado: (2008)

Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism
por: Damle, Bharat, et al.
Publicado: (2020)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
por: Trujillo‐Santos, Javier, et al.
Publicado: (2022)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial
por: Yhim, Ho-Young, et al.
Publicado: (2019)

Fatigue after initiating rivaroxaban for venous thromboembolism
por: Karlsvik, Tina Margrethe, et al.
Publicado: (2020)

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Speed, Victoria, et al.
Publicado: (2021)

Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement
por: Dranitsaris, George, et al.
Publicado: (2011)

Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients
por: Li, Guowei, et al.
Publicado: (2015)

A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY
por: Kim, Jwa Hoon, et al.
Publicado: (2022)

Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors
por: Cook, Deborah, et al.
Publicado: (2008)

Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis
por: Arce-Huamani, Miguel A., et al.
Publicado: (2023)

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
por: Harder, Sebastian
Publicado: (2014)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis
por: Dranitsaris, George, et al.
Publicado: (2017)

Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial
por: Becattini, Cecilia, et al.
Publicado: (2021)

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)
por: Longo de Oliveira, André Luiz Malavasi, et al.
Publicado: (2022)

Characteristics and Effect of Rivaroxaban on Venous Thromboembolism in Korean Patients Compared to Western Population: A Subgroup Analysis from XALIA(-LEA) Study
por: Min, Seung-Kee, et al.
Publicado: (2022)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism
por: UCHIDA, Mona, et al.
Publicado: (2020)

Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry
por: Speed, Victoria, et al.
Publicado: (2021)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

Venous Thromboembolism in Japanese Patients with Gynecologic Cancer
por: Suzuki, Takahito, et al.
Publicado: (2023)

Venous Thromboembolic Complications in Colorectal Surgery
por: Huh, Jung Wook
Publicado: (2015)

New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban
por: Borris, Lars Carl
Publicado: (2008)

Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery
por: Du, Wei, et al.
Publicado: (2015)

Use of rivaroxaban in sickle cell disease and venous thromboembolism: A case report
por: Rozi, Waail, et al.
Publicado: (2021)

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
por: Reda, Sara, et al.
Publicado: (2022)

Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
por: Migita, Shohei, et al.
Publicado: (2023)

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis
por: Liu, Zhuang, et al.
Publicado: (2023)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

Updated recommendations for the treatment of venous thromboembolism
por: Hong, Junshik, et al.
Publicado: (2021)

Predicting Perioperative Venous Thromboembolism in Japanese Gynecological Patients
por: Ikeda, Masae, et al.
Publicado: (2014)

Predicting of Venous Thromboembolism for Patients Undergoing Gynecological Surgery
por: Qu, Hong, et al.
Publicado: (2015)

Rivaroxaban after Thrombolysis in Acute Iliofemoral Venous Thrombosis: A Randomized, Open-labeled, Multicenter Trial
por: Kang, Jin Mo, et al.
Publicado: (2019)

A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment
por: Woodruff, Seth, et al.
Publicado: (2016)

Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban()
por: Colleoni, Jose Luiz, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0d0pjgek6uf3jla5i9s5o4hunq